| Project/Area Number |
12671526
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
EHARA Hidetoshi Gifu University School of Medicine, lecturer, 医学部, 講師 (20252132)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHINO Yoshinori Gifu University School of Medicine, lecturer, 医学部・附属病院, 助手 (90281055)
DEGUCHI Takashi Gifu University School of Medicine, professor, 医学部, 教授 (40163935)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2001: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2000: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | urogenital cancers / anticancer-resistance / DNA chip / real-time RT-PCR / chemosensitivity test |
|---|
| Research Abstract |
To develop the new DNA microarrays superior to chemosensitivity test in urogenital cancers, we conducted a series of experiments on cell lines. Before the design of DNA chips, we synthesized a series of paired primers against genes for anticancer drug resistance associated proteins. We designed these primers to use real-time RT-PCR, simultaneously. After the fundamental experiments, we measured the expression of MDR1 mRNA by a quantitative RT-PCR (LightCycler, Roche Co.) in cancerous samples of patients undergoing surgery or biopsy (n=504), and compared with chemosensitivity test (MTT assay) in clinical specimens of uroepithelial carcinomas and renal cell carcinomas (n=43). Despite this high incidence of MDR1 expression in renal cell carcinoma no obvious association with clinicopathological parameters was found. Further, we did not find the significant associations between MOR1 expression and clinicopathological findings in prostate cancers and uroepithelial cancers. The measurement of MDR1 expression of uroepithelial cancers did not associated with the degree of resistance to anticancer drugs including doxorubicin.
|
